Author

C. Hartley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Pharmacology & Toxicology· 1 Scientific Communication & Education· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Approach:statistical model· 2 Research Focus:variant calling· 2 Assay:whole-genome sequencing· 2 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

J. A. Hiscox· 4 shared H. Goldswain· 3 shared R. Penrice-Randal· 3 shared T. Prince· 3 shared B. Jones· 2 shared ISARIC4C investigators· 2 shared J. K. Baillie· 2 shared L. Turtle· 2 shared

Activity by Year

2020-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

J. A. Hiscox

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Rapid selection of P323L in the SARS-CoV-2 polymerase (NSP12) in humans and non-human primate models and confers a large plaque phenotype

X. Dong, H. Goldswain, R. Penrice-Randal, G. Shawli, T. Prince, M. K. Williamson, N. Randle, B. Jones, F. J. Salguero, J. Tree, Y. Hall, C. Hartley, M. Erdmann, J. Bazire, T. Jearanaiwitayakul, , J. A. Hiscox

The paper tracks the rapid emergence of the P323L mutation in SARS-CoV-2 polymerase in human and non-human primate models, showing it confers a larger plaque phenotype compared to P323.

bioRxiv · Dec 23, 2021 · PreprintMicrobiology

Antiviral activity of molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and implications for the therapeutic window and resistance

T. Prince, I. Donovan-Banfield, H. Goldswain, R. Penrice-Randal, C. Hartley, T. Fletcher, S. Khoo, J. A. Hiscox

This study evaluates the antiviral activity of molnupiravir's active metabolite NHC against SARS-CoV-2 variants, finds no resistance after 20 passages, and suggests earlier administration for better efficacy.

bioRxiv · Nov 23, 2021 · PreprintMicrobiology

Using Oxford Nanopore Technology direct RNA sequencing to identify depurination events induced by ricin and other ribosome inactivating proteins

Y. Ryan, A. J. Harrison, H. Trivett, C. Hartley, J. David, G. Clark, J. A. Hiscox

bioRxiv · Aug 13, 2021 · PreprintPharmacology & Toxicology

Sequence analysis of SARS-CoV-2 in nasopharyngeal samples from patients with COVID-19 illustrates population variation and diverse phenotypes, placing the in vitro growth properties of B.1.1.7 and B.1.351 lineage viruses in context.

T. Prince, X. Dong, R. Penrice-Randal, N. Randle, C. Hartley, H. Goldswain, B. Jones, M. G. Semple, J. K. Baillie, P. J. M. Openshaw, L. Turtle, ISARIC4C Investigators, G. Hughes, E. Anderson, E. I. Patterson, , J. A. Hiscox

The paper analyzes SARS-CoV-2 sequence variation in patient samples and compares the in vitro growth of B.1.1.7 and B.1.351 variants to other isolates, finding no significant difference in growth for B.1.1.7.

bioRxiv · Mar 30, 2021 · PreprintMicrobiology

A retrospective analysis of gender parity in scientific authorship in a biomedical research centre

R. Dam, S. G. S. Shah, M. J. Milano, L. D. Edmunds, L. R. Henderson, C. Hartley, O. Coxall, P. V. Ovseiko, A. M. Buchan, V. Kiparoglou

This study analyzes gender parity in authorship categories across biomedical research publications and finds female authors are underrepresented in all six authorship roles.

bioRxiv · Feb 24, 2020 · PreprintScientific Communication & Education